Replimune Group, Inc. (REPL)
8.23
0.00 (0.00%)
USD |
NASDAQ |
Jan 09, 13:16
Replimune Group Research and Development Expense (Annual): 191.22M for March 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Rapt Therapeutics, Inc. | 107.22M |
| Olema Pharmaceuticals, Inc. | 124.52M |
| CorMedix, Inc. | 3.942M |
| Verastem, Inc. | 81.33M |
| Anavex Life Sciences Corp. | 37.59M |